Jordan Gainey

#SUO25 📢TiP: IDeate-Prostate01 🧪 I-DXd (B7-H3 ADC) vs docetaxel in post-ARPI mCRPC 👥 ~1,440 pts | 1–2 prior ARPIs | global phase 3 🔹 Dual primary: OS & rPFS 🔹 Stratified by mets pattern, B7-H3 level, prior PSMA Tx ✅ Targeting B7-H3: novel ADC with promising early signals @UroToday @UroOnc

⚡️ #SUO25 LBA - Neo-SAbR: Ph II Trial of Neoadj SABR to IVC TT in RCC @urotoday @UTSWUrology 🌞n=23, neoadjv 40 Gy/5 fr or 36 Gy/3 fr SABR 🌞Prim EP (+ve trial): 1-yr RFS @ 12 mo: 71.4% (80%CI 56.6–82.0%; p=0.087) 🌞TT ⬇️staging: 22.7% 🌞0 RT Gr 4+ AEs 🌞36.4% periop Gr 3+ AEs

New research from @jsunny99 @thayerschool reveals FLASH radiotherapy's normal tissue sparing effect requires sequential deliveries to be within ~10s—matching tissue reoxygenation time. Split-dose study provides key evidence linking oxygen dynamics to the FLASH effect. Read about it in the #RedJournal: tinyurl.com/rjsunnerberg

💥 The @OncoAlert #GUOncology team has once again delivered an outstanding lineup! 🙌 Excited to discuss these studies live at #ESMO25 Berlin 🇩🇪 From PSMAaddition to RAMPART and KEYNOTE-905, the GU field is stronger than ever. Which one are you most looking forward to? 💬 🌍 Follow the global dream team: #OncoAlertAF 🇺🇸 @WeOncologists 🇧🇪 @ElisaAgostinett 🇦🇷 @nataliagandur 🇮🇹 @to_be_elizabeth 🇫🇷 @acampsmalea 🇺🇸 @BRicciutiMD 🇯🇵 @HHorinouchi 🇺🇸 @Abdallah81MD 🇧🇷 @bavilima 🇧🇷 @FernandoOnco 🇺🇸 @realbowtiedoc 🇹🇷 @Erman_Akkus 🇮🇹 @Lucarecco 🇮🇹 @GaiaGriguolo 🇷🇸 @JankovicK 🇪🇸 @MarioBalsaMD 🇪🇸 @DrMirallas 🇺🇸 @GIMedOnc  🇹🇷 @UOzkerim 🇮🇳 @DrRishabhOnco 🇲🇽 @ReginaBarCar

The phase 3 PSMAddition trial has met its primary end point, showing that lutetium (177Lu) vipivotide tetraxetan plus SOC significantly improved rPFS vs SOC alone in patients with PSMA-positive mHSPC. #pcsm urologytimes.com/view/adding-lu…

Check out the latest @ASCO guidelines on functional NETs. While management of well-differentiated NETs is often nuanced, three critical factors should be assessed at the initial visit to guide an effective treatment plan: 1.Tumor Grade 2.Disease Stage 3.Functional Status ➡️ascopubs.org/doi/10.1200/OP…

Re-irradiation is common but challenging in lung cancer. ARS just published: American Radium Society™ Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer Executive Summary. My personalized Share Link: authors.elsevier.com/c/1l3k51Hx52Ni…

New @JCO_ASCO publication featuring @DukeCancer #RadOnc authors: "Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment" – congrats! 🔗ascopubs.org/doi/10.1200/JC…

Meningioma Grading Will Never Be the Same: 🔑 Takeaways from cIMPACT-NOW Update 8 @OncoAlert For oncologists & radiation oncologists: here’s what you need to know about the molecular era of meningiomas🧵(1/14)

Carboplatin + involved node radiotherapy (INRT) is now a treatment option for seminoma stage IIA/B in the latest version of the #NCCN Guidelines . Thank you to all patients who took part in #SAKK0110 & #SAKK0118 and to all collaborators. @sakk_ch

#PSMAandBeyond2025 212Pb-PSMA vs 225Ac-PSMA: from biology to supply. Presentation by Alfred Morgenstern, PhD. Written coverage by @zklaassen_md @GACancerCenter > bit.ly/4jaSiiG @PSMAconference @PCFnews

#PSMAandBeyond2025: Overview of clinical trials of PSMA RLT in 2025. Presentation by @CalaisJeremie @UCLAHealth. Written coverage by @zklaassen_md @GACancerCenter > bit.ly/4l8B6vV @PCFnews @PSMAconference

Potential Impact of LDRT: The addition of LDRT appears to have mitigated some of the degenerative changes typically seen in osteoarthritis progression, suggesting a potential protective or slowing effect on joint deterioration.

WOLVERINE Study: 5 trials of 472 oligometastatic prostate cancer patients followed for a median of 41 months. urotoday.com/video-lectures… a través de @urotoday

Decipher GC for predicting treatment prog in AS pts, adjusted for mpMRI findings (n=338; f/u: 26 mo) 🔹GC score ≥0.45 assoc w/ ⬆️rate of tx prog in both pts with PI-RADS 1-3 & 4-5 lesions (HR: 1.6, p=0.05) 🔹mpMRI PI-RADS 4-5 lesions not assoc w/ rate of tx prog in pts with GC score ≥0.45 📍Findings further support NCCN recs to consider incorporation of Decipher for risk strat of clinically localized PCa pts @urotoday #SUO24

💫🌟#PROSCA24 @mirrorsmed @OncoAlert🌟💫

How do we talk about (and report) #reirradiation? There's been quite a lot of variation in the literature - including basic spelling! We agreed on a set of standard nomenclature & terminology in the @ESTRO_RT Physics reRT working group sciencedirect.com/science/articl… #medphys #radonc

Happy to announce that the PEACE 6 OligoPRESTO trial testing the role of metastasis directed therapy in hormone sensitive #ProstateCancer has completed accrual ahead of schedule. 550 patients randomized. Waiting now for data to mature.

225Ac-PSMA / 177Lu-PSMA tandem therapy for #mCRPC – a prospective phase 3 randomized study from #Azerbaijan. Presentation by Fuad Novruzov, MD, PhD. #SNMMI24 written coverage by @RKSayyid @UofT > bit.ly/4aU76O8 @Olympus5 @SNM_MI